Introduction
Erectile dysfunction (ED) is defined by the National Institutes of Health as 'the inability of the male to achieve or maintain an erection sufficient for satisfactory sexual performance'. 1 Estimates suggest that ED affects approximately 150 million men worldwide, and the rates of ED are expected to double by the year 2025. 2, 3 ED negatively impacts quality of life of both men with the condition and their female partners. 4 A number of therapeutic options are available to treat men with ED; of these, oral phosphodiesterase type 5 (PDE5) inhibitors are recommended as a first line of therapy. As the introduction of tadalafil, a PDE5 inhibitor, several analyses have been conducted to fully understand the breadth of its clinical
benefits. An integrated analysis of 11 randomized, double-blind, placebo-controlled clinical trials of tadalafil demonstrated its efficacy and safety across various subgroups of patients. 5 Analysis has shown that tadalafil is effective regardless of pretreatment severity of ED, with clinically meaningful improvement reported in patients with mild to severe ED at baseline (BL). [5] [6] [7] Studies including patients with comorbid clinical conditions such as hyperlipidemia, hypertension and cardiovascular disease have also delineated the efficacy of tadalafil therapy. 5, 8 In addition, numerous clinical trials have been conducted to evaluate response to therapy in various hard-to-treat populations of men with ED, for example, those with diabetes 9 and those who are post prostatectomy. 10 Clinically meaningful responses in these groups of patients have additionally helped to characterize the benefits of therapy. On review, health care practitioners (HCPs) have a myriad of clinical trial results that can assist them in the effective management of ED. For example, McCullough et al. [11] [12] [13] have examined achieving treatment optimization in patients with ED, focusing on improved dialogue between physician and patient, understanding expectations, the relation-ship between number of intercourse attempts and successful intercourse, as well as education and counseling.
From the patient perspective, men seeking therapy for their ED present foremost with reflections of the success or failure of their recent attempts at sexual intercourse. Patients presenting to their doctor as having 'no success' may embody the emotional and psychological strains of ED, be somewhat disillusioned by their current state, and may be desperate to find effective therapy, yet potentially pessimistic about treatment alternatives.
14 This could present a barrier to seeking treatment. A study of an international cohort of over 32 000 men showed that among barriers to seeking treatment for ED was the belief that nothing could be performed about it, and this belief was strongly associated with the severity of ED. 15 To date, no study has focused specifically on treatment outcomes among men experiencing no success with intercourse attempts before initiation of ED therapy.
From the HCP perspective, a number of questions exist: What response can they provide to the patient? What outcome can they reasonably expect when prescribing an ED treatment to a patient? What evidence is there to support the treatment plan?
The purpose of this retrospective analysis was to evaluate the results of a clinical trial from a unique perspective, in which the response to sexual intercourse attempts before therapy in patients with ED served as the study criteria. Patients either reported 'no success at baseline', that is, failures in all sexual intercourse attempts before the initiation of treatment (negative response to question 3 of the sexual encounter profile (SEP) diary, 'Did your erection last long enough for you to have successful intercourse?' [SEP3]) or 'some success at baseline', that is, at least one successful intercourse attempt (positive response to SEP3).
Subsequent responses were analyzed to determine the outcomes of patients receiving therapy based on this criterion to characterize these subgroups.
Materials and methods
This descriptive analysis was performed using data from the multiple observations in men with ED in the National Tadalafil Study in the United States (MOMENTUS) trial, which was a multicenter, openlabel study with a unique noninferiority design conducted at 187 clinical sites in the United States. 16 The study was reviewed and approved by the ethics review boards at each participating site, and all patients provided written informed consent consistent before undergoing any protocol procedure or receiving any protocol treatment. The purpose of the trial was to evaluate the efficacy and safety of tadalafil at a dose of 20 mg as needed, up to once daily, over a 12-week period in populations of men with ED, including those from different ethnic backgrounds (Caucasian, Hispanic and Black) and those with various ED risk factors, such as diabetes, clinical diagnosis of depression or spinal cord injury. The study was completed in 2004, and enrolled 1911 male patients who were at least 18 years of age and who had experienced ED for at least 3 months. Each patient was to report on his sexual intercourse attempts with the same adult female partner. Patient exclusion criteria were discussed in a previous report. 16 Briefly, patients were excluded if they had a recent history of stroke, unstable cardiovascular status, use of nitrates, cancer chemotherapy, anti-androgens, failure to achieve any erection due to radical prostatectomy or pelvic surgery, or clinically significant penile deformities or penile implants and who did not respond, in the opinion of the investigator, to previous use of other PDE5 inhibitors.
The study consisted of two phases. The first phase was a 4-week, treatment-free run-in period without ED medications, to establish BL function. During this period, patients were asked to make at least four sexual intercourse attempts with their female partner and to record responses to these attempts in the SEP diary. The second phase consisted of 12 weeks of treatment in which patients took a fixed dose of tadalafil (20 mg as one tablet) as needed before a sexual intercourse attempt, up to a maximum of one dose per day. During the treatment phase, patients were asked to make at least four intercourse attempts over each 4-week period. Response to therapy was captured with the SEP diary and the International Index of Erectile Function (IIEF) instrument.
Main outcome measures
Outcome measures included the SEP diary and the IIEF. Assessments of individual sexual attempts were obtained through the patients' SEP diaries throughout the 4-week run-in period and during the 12-week treatment period. Patients recorded the day and time of dosing and time and outcome of each sexual intercourse attempt with their female study partners. SEP question 3, 'Did your erection last long enough for you to have successful intercourse? (yes/ no)' was used to determine intercourse success at BL and during the treatment period. Patients were determined to have either 'no success', that is, answered 'No' to SEP3 for all sexual intercourse attempts or 'some success', that is, answered 'Yes' to SEP3 for at least one sexual intercourse attempt. For example, if a patient answered 'No' to SEP3 for all sexual intercourse attempts during the BL period, then he had no success at BL; and if a patient answered 'No' to SEP3 for all sexual intercourse attempts during the treatment period, then he had no success at the end of treatment (study end point, EP).
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International Index of Erectile Function-Erectile Function (IIEF-EF) 17 domain scores were measured at BL and EP to reflect response to therapy. In addition, severity of ED among patients with 'no success' at BL and those with 'some success' at BL was determined using the EF domain score, which classifies patients into five categories: normal/no ED (EF score ¼ 26-30), mild ED (EF score ¼ 22-25), mild to moderate ED (EF score ¼ 17-21), moderate (EF score ¼ 11-16) and severe ED (EF score ¼ 6-10). Scores less than 6 indicate the patient made no sexual intercourse attempts during the assessment period. 18 Statistical analysis Demographics were summarized for two groups of patients: patients with no intercourse success at BL and patients with some success at BL. Age was treated as a continuous variable. Etiology of ED, BL ED severity and comorbid conditions were treated as categorical variables. Summary statistics for continuous variables included mean and standard deviation. Categorical variables were presented as counts and percentages. Comparisons between scores on the IIEF-EF domain at BL and at study EP were evaluated using paired t-tests for the following seven groups of patients: all enrolled patients, patients with no intercourse success at BL, patients with some intercourse success at BL, patients with no success at either BL or study EP, patients with no success at BL but some success at study EP, patients with some success at BL but no success at study EP and patients with some success at both BL and study EP. These subgroups are schematically presented in Figure 1 .
Results

Study population
Of the 1911 patients enrolled, 1641 (85.9%) completed the 12-week treatment phase. 16 Overall results showed tadalafil to be effective, with an EP IIEF-EF domain score of 24.6 (change from BL of 9.9 points).
Patients' disposition and reasons for discontinuation from the study are discussed in a previous publication. Among the enrolled patients, the most common reasons for study discontinuation were lost to follow up, adverse events, patient decision and perceived lack of efficacy. 16 In addition to this attrition, some patients did not complete all study measures, in particular SEP3 post-BL and IIEF-EF at study EP. Figure 1 presents the numbers of patients who were categorized into the various subgroups as determined by their SEP3 responses indicating success or lack of success in intercourse attempts at BL and study EP. One-half (n ¼ 952, 49.9%) of the 1907 patients with BL SEP3 scores reported no successful intercourse attempts during the 4-week treatment-free BL period (that is, no pretreatment success), and one-half (n ¼ 955, 50.1%) reported Tadalafil response after no baseline success R Shabsigh et al at least one successful intercourse attempt during BL. The demographics of patients in both of these groups are reported in Table 1 . Compared with patients with some success at BL, patients who reported no pretreatment successful intercourse attempts were slightly older (56.8 vs 53.4 years), had a higher incidence of comorbid conditions, and a greater proportion of them reported severe ED at BL (60.6 vs 6.5%).
Outcomes of patients with no success at BL For the 952 patients with no pretreatment success, their score as a group on the IIEF-EF domain improved from a mean of 10.3 at BL to 22.2 at EP (Po0.001) (Figure 2 ). A minority (n ¼ 141, 14.8%) of patients with no pretreatment success continued to have no success during treatment. For this group of patients, the mean IIEF-EF score changed from 7.6 at BL to 9.8 at EP (Po0.001) and the distribution of IIEF-EF scores ( Figure 3 ) remained relatively unchanged following treatment. However, the majority of patients (771, 81.0%) with no BL success responded to treatment by having at least one successful intercourse attempt during the tadalafil treatment period. For these patients, the mean IIEF-EF domain score increased from 10.8 at BL to 24.4 at EP (Figure 4 ) (Po0.001). Post-BL SEP3 responses were not available for 40 (4.2%) patients. Additional analyses indicated that 709 patients (74.5%) had at least three successful attempts during the treatment period, and 654 (68.7%) had at least six successful sexual intercourse attempts during treatment.
The demographic and BL characteristics of patients with no pretreatment success who either had no success with treatment (n ¼ 141) or who had some success with treatment (n ¼ 771) are presented in Table 2 . Compared with patients who had success Outcomes of patients with some success at BL One-half of the patients (n ¼ 955, 50.1%) reported at least one successful intercourse attempt during the BL period as documented by a 'yes' response to Tadalafil response after no baseline success R Shabsigh et al SEP3. Of this group, patients who continued to have intercourse success through the treatment period showed IIEF-EF domain scores that improved from 19.0 at BL to 27.2 at EP (Po0.001) ( Figure 5 ). This improvement in EF was numerically comparable to that of patients with no success at BL but success with treatment (IIEF score 10.8 at BL to 24.4 at EP). Less than 1% of patients (n ¼ 13) who had successful intercourse attempts at BL reported no success at the end of treatment. Regardless of whether patients had success before treatment, the distribution of efficacy responses for patients having some intercourse success with treatment ( Figures 4 and 5) shows a similar pattern of response, with a distribution shift indicating more patients in the mild (IIEF 22-25) to normal (IIEF 26-30) ED categories 18 following treatment.
Discussion
Treatment with oral PDE5 inhibitors, such as tadalafil, has been shown to be efficacious in men with ED regardless of ED severity at BL, ED etiology and comorbid medical conditions. 5, 7, 19 Given the negative impact of ED on men's sexual self-esteem, quality of life, and interpersonal relationships, 1, 20 it is clearly important to provide effective treatments for this condition.
The analysis discussed in this paper was unique in that it captured a typical clinical presentation of a patient to his HCP. HCPs often encounter patients who report 'no success' with sexual intercourse. These patients might be expected to be at higher risk of treatment failure; however, in this study, 81.0% of patients who reported no pretreatment success responded to treatment with tadalafil. Their improvement in EF as measured by change in IIEF-EF domain scores, was clinically relevant (that is, greater than 4 points), 21 and was numerically comparable to that of the group as a whole and the subgroup of patients who experienced some pretreatment success. Thus, the population of men who declared 'no success' was indeed responsive as a group to therapy.
The mean IIEF-EF score for the 14.8% of patients who reported no successful intercourse at BL and at the end of the study changed only from 7.6 (BL) to 9.8 (EP). Although statistically significant, this increase is not considered clinically meaningful. 21 Review of this group of patients revealed them to be older and with more severe ED at BL. Also, there was a higher incidence of cardiovascular disease in this group. For the clinician, this group would be the ideal population for further diagnostic evaluation, treatment of cormorbid conditions, and may be potential candidates for other forms of ED treatment, such as penile injection therapy, vacuum erection device, or some combination of pharmacotherapy and psychosocial counseling.
In this analysis, 'some success' was broadly defined as at least one successful sexual intercourse attempt during the BL and treatment periods as measured by SEP3. Although perhaps considered a conservative goal of therapy, this positive response may be significant to a patient with a recent experience of failure. Furthermore, when more stringent criteria of success (that is, at least three and at least six successful attempts) were applied, the majority of patients with no success at BL also reported success with treatment. For the treating HCP, the results of this analysis may assist the HCP to convey reasonable expectations of success to treatment.
Not all of the patients enrolled in this study completed all study measures; some patients (14.1%) were lost to follow-up or discontinued early. As IIEF was captured at end of therapy, responses for all enrolled patients were not obtained. It is believed that missing data did not affect the overall outcomes of this analysis.
There was some variability in IIEF-EF scores among men with no success at BL. One would anticipate that no success at BL would be a result of patients having severe ED. Interestingly, despite the lack of successful intercourse attempts during the 4-week run-in period, 39.4% of these patients had IIEF-EF scores that reflected a mild to at most moderate BL ED severity: moderate (24.6%), mild to moderate (12.1%), mild (2.3%) or no ED (0.4%). The distribution of EF domain scores before treatment reflects multiple patient and partner factors and potentially trial-specific effects before and during the monitoring period of the study. Other studies Tadalafil response after no baseline success R Shabsigh et al suggest that multiple variables, including patient and partner issues, may contribute to erectile response. 22 It should be noted that the majority of the patients with no pretreatment success and severe ED at BL (n ¼ 575; Table 1 ) did have some success with treatment (n ¼ 428, 74.4%), which supports the effectiveness of tadalafil in improving EF for men with severe ED. 7, 19 Overall, this information is encouraging for men with severe ED who may otherwise not seek treatment because they believe that nothing can be performed about it. 15 Understanding that treatment of ED may be successful even in the most severe ED cases, may help many men, who otherwise suffer in silence, overcome the barriers and seek treatment.
Conclusions
Approximately, one-half of the patients in the MOMENTUS trial reported having no successful intercourse before treatment. However, the majority (81.0%) of these patients responded to treatment with tadalafil as demonstrated by at least one successful intercourse attempt. As a group, these patients showed improvements in EF comparable to that of patients who had some intercourse success before treatment. Mean IIEF-EF scores at study EP were comparable for all groups of patients who responded to treatment, regardless of their success rate at BL. These results suggest that patients who clinically present with no recent intercourse success are likely to respond to treatment. Patients with ED should be encouraged to seek treatment and HCPs, based on the results of this analysis, should feel comfortable conveying favorable expectations of a successful response to treatment.
